A Phase 1/2 interventional study of SRP-5051 in Muscular Dystrophy, Duchenne, sponsored by Sarepta Therapeutics, Inc.. Terminated at 8 sites in 2 countries. Open to male participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2018, is one of 5 in phase 1/2, and was the 14th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 2+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States, Belgium, Germany and 6 more countries
Men only
Sarepta Therapeutics, Inc. · Sites in United States
Men only
By country, each count listing its studies:
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 4 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 7 · Phase 4 1
First in 2009; this study’s year is marked. 5 started in 2018.
This study's enrollment of 15 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 24 across the 25 interventional studies, 400 across the 2 observational. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
2 of the studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT07542314Sarepta Therapeutics, Inc.Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this extension study is to evaluate the safety, tolerability, and pharmacokinetics of repeat administrations of SRP-5051 (vesleteplirsen) in participants with Duchenne muscular dystrophy (DMD) who participated in studies of SRP-5051.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion/exclusion criteria apply.
* The dose of steroids must remain constant except for modifications to accommodate changes in weight.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive SRP-5051 via intravenous (IV) infusion. Dosage and frequency will be determined from the safety profile of other ongoing SRP-5051 studies.
Drug: SRP-5051
SRP-5051 administered as an IV infusion.
Also known as: vesleteplirsen
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
A TEAE was any untoward medical occurrence in a clinical study participant that did not necessarily have a causal relationship with the study drug. A TEAE could, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurred during or after administration of the study drug, whether or not considered related to the study drug. A summary of serious and all other non-serious TEAEs regardless of causality is located in the Reported Adverse Events module.
Time frame: Up to approximately 135 weeks
Plasma Concentration of SRP-5051
For pharmacokinetic (PK) analysis, plasma samples were collected pre-dose (approximately 30 minutes prior to the start of infusion), immediately prior to the end of infusion (prior to flush), and approximately 4 to 6 hours after the end of dosing. Results are reported in micrograms/liter (ug/L) and are presented as an average across the days specified in the time frame.
Time frame: Day 1, Day 84, every 84 days after Day 84 (up to a maximum of approximately 135 weeks) (pre-dose, immediately prior to end of infusion, up to 4-6 hours post-dose)
| Milestone | SRP-5051 |
|---|---|
| Started | 15 |
| Received at least 1 dose of study drug | 15 |
| Completed | 0 |
| Not completed | 15 |
| Withdrew: Study terminated by sponsor | 9 |
| Withdrew: Death | 2 |
| Withdrew: Withdrawal by subject | 4 |
A TEAE was any untoward medical occurrence in a clinical study participant that did not necessarily have a causal relationship with the study drug. A TEAE could, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurred during or after administration of the study drug, whether or not considered related to the study drug. A summary of serious and all other non-serious TEAEs regardless of causality is located in the Reported Adverse Events module.
| Participants | SRP-5051 |
|---|---|
| Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | 14 |
For pharmacokinetic (PK) analysis, plasma samples were collected pre-dose (approximately 30 minutes prior to the start of infusion), immediately prior to the end of infusion (prior to flush), and approximately 4 to 6 hours after the end of dosing. Results are reported in micrograms/liter (ug/L) and are presented as an average across the days specified in the time frame.
| ug/L | SRP-5051 |
|---|---|
| Pre-dose | 486.25 ± 7717.595 |
| End of Infusion | 45244.93 ± 42639.411 |
| 4-6 Hours Post-dose | 2790.32 ± 10941.464 |
Collected over Up to approximately 135 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SRP-5051 | 2/15 (13.3%) | 6/15 (40%) | 14/15 (93.3%) |
| Event | SRP-5051 |
|---|---|
| HypomagnesaemiaMetabolism and nutrition disorders | 2/15 |
| AnaemiaBlood and lymphatic system disorders | 1/15 |
| Cardiac arrestCardiac disorders | 1/15 |
| Cardiogenic shockCardiac disorders | 1/15 |
| CardiomyopathyCardiac disorders | 1/15 |
| Colitis ischaemicGastrointestinal disorders | 1/15 |
| IleusGastrointestinal disorders | 1/15 |
| DehydrationMetabolism and nutrition disorders | 1/15 |
| Electrolyte imbalanceMetabolism and nutrition disorders | 1/15 |
| HypokalaemiaMetabolism and nutrition disorders | 1/15 |
| Event | SRP-5051 |
|---|---|
| HypomagnesaemiaMetabolism and nutrition disorders | 7/15 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/15 |
| ContusionInjury, poisoning and procedural complications | 3/15 |
| FallInjury, poisoning and procedural complications | 3/15 |
| Back painMusculoskeletal and connective tissue disorders | 3/15 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 3/15 |
| Abdominal painGastrointestinal disorders | 2/15 |
| DiarrhoeaGastrointestinal disorders | 2/15 |
| DysphagiaGastrointestinal disorders | 2/15 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/15 |
Safety Set: all participants who started the study drug infusion.
| Age, Continuous(years) | SRP-5051 |
|---|---|
| Mean | 16.5 ± 2.80 |
| Sex: Female, Male(Participants) | SRP-5051 |
|---|---|
| Female | 0 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | SRP-5051 |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | SRP-5051 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
Ran from Dec 2018 to primary completion in Aug 2021, 32 months.
Results were first posted in Sep 2024, 3 years after primary completion. A results delay was requested in Aug 2022.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vesleteplirsen
Muscular Dystrophy, Duchenne →